Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies ...

Immunotherapy has transformed the field of medicine. In the context of cancer, immune cells become dysregulated and lose the ...

The data showed that a subset of killer T cells that also interact with EBV are more prevalent in people with the chronic autoimmune disease.

Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with ...

Targeted therapies, bispecifics, and CAR T-cell therapies are giving patients with multiple myeloma hope for long-term remission or a potential cure.

Jessica Adams showcases some of the lifesaving developments supported by your donations ...

An infection with Epstein-Barr virus is a nonevent for most people. But for a subset, the virus can contribute to chronic ...

“By dividing and conquering…we’re seeing responses in multiple different subtypes of sarcoma…and moving toward more of an individualized therapy that we try to design for every patient, where we take ...

Nonresponse to bridging therapy and high lymphocyte count were predictive of parkinsonism and nonrelapse mortality (NRM) after treatment with ciltacabtagene autoleucel (cilta-cel; Carvykti) in ...

This article was reviewed by Felix Gussone, MD. Key Takeaways: Your endocrine system regulates many bodily functions, from ...

Pregnancy is, biologically speaking, a state of controlled upheaval. The immune system recalibrates. Blood volume surges. And ...

(Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced the publication of results from a prior Phase 2 clinical study evaluating ...